Save up to 90% on Sarilumab with Coupons, Discount Cards & Patient Assistance Programs

Sarilumab is available as a 150 mg/1.14 mL or 200 mg/1.14 mL single-dose pre-filled syringe or pen.

Sarilumab is a monoclonal antibody that is used to treat the following:

• Moderate-to-severe rheumatoid arthritis (RA)
  Polymyalgia rheumatica (PMR)

Sarilumab is a monoclonal antibody that’s called an interleukin-6 inhibitor. Interleukin-6 (IL-6) is a protein in your body that plays a key role in causing inflammation in your joints, leading to symptoms like joint swelling and pain. By blocking IL-6, it lowers inflammation and helps relieve symptoms.

The typical dose is 200 mg injected under the skin once every 2 weeks. Your provider might lower your dose based on your lab test results (e.g., blood cell counts, liver tests) and whether you’re having side effects (e.g., infections).

Sarilumab is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Sarilumab:

• Low white blood cell count
• High liver enzyme levels
• Redness at injection site
• Upper respiratory tract infection
• Urinary tract infection
• Muscle pain

Serious side effects are rare with Sarilumab. Contact your healthcare provider immediately if you experience any of the following.

• Serious infections: fever, difficulty breathing, cough, weakness, sweating, chills, diarrhea, stomach pain, burning when you urinate, urinating more frequently
• Tears in the stomach (perforation): fever, chills, stomach pain that won’t go away, sudden and severe stomach pain, nausea, vomiting, stomach swelling or bloating
• Serious allergic reactions: hives, rash, blisters, skin reddening, swelling of the lips or tongue, difficulty breathing

• The following medications may interact with Sarilumab:
• Exercise caution when co-administering Sarilumab with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc. The effect of Sarilumab on CYP450 enzyme activity may persist for several weeks after stopping therapy
• Avoid concurrent use of live vaccines during treatment with Sarilumab

Various FDA-approved generic manufacturers

It is not known if Sarilumab will harm your unborn baby. Tell your healthcare provider if you become pregnant while taking Sarilumab.

• Kevzara